Laboratory test differences associated with HTLV-I and HTLV-II infection

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 17, Issue 4, 1998, Pages 332-338

  Murphy, Edward L ^a,g   Glynn, Simone ^b   Watanabe, Kevin ^b   Fridey, Joy ^c   Smith, James ^d   Sacher, Ronald ^e   Wright, David ^b   Schreiber, George ^b   Luban, Naomi ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WESTAT   (United States)

^c Blood Bank of San Bernardino and Riverside Counties   (United States)

^d Oklahoma Blood Institute   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcium; Creatine kinase; Eosinophil count; HTLV I; HTLV II; Lactic dehydrogenase; Lymphocyte count; Mean corpuscular volume; Platelet count

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; CALCIUM; CREATINE PHOSPHATE; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; CALCIUM BLOOD LEVEL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEMOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; ERYTHROCYTE VOLUME; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INFANT; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PARASITOSIS; PRIORITY JOURNAL; THROMBOCYTE COUNT;

HTLV; HTLV II; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2;

EID: 0031943770     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199804010-00007     Document Type: Article

References (37)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77:7415-9.
2. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, et al. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982;218: 571-3.
3. Gessain A, Gout O. Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1992;117: 933-46.
4. Kramer A, Maloney EM, Morgan OS, et al. Risk factors for human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/ tropical spastic paraparesis (HAM/TSP) in Jamaica. Am J Epidemiol 1995;142:1212-20.
5. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA 1984;81:2534-7.
6. Mochizuki M, Watanabe T, Yamaguchi K, et al. HTLV-I uveitis: a distinct clinical entity caused by HTLV-I. Jpn J Cancer Res 1992;83:236-9.
7. Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y, Osame M. Chronic inflammatory arthropathy associated with HTLV-I. Lancet 1989;1:441.
8. Mita S, Sugimoto M, Murakami T, et al. Increased human T-lymphotropic virus type-1 (HTLV-1) proviral DNA in peripheral blood mononuclear cells and bronchoalveolar lavage cells from Japanese patients with HTLV-1-associated myelopathy. Am J Trop Med Hyg 1993;48:170-7.
9. Morgan OS, Rodgers-Johnson P, Mora C, Char G. HTLV-I and polymyositis in Jamaica. Lancet 1989;2:1184.
10. Murphy EL, Fridey J, Smith JW, et al. HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II infected blood donors. Neurology 1997;48:315-20.
11. Modahl LE, Young KC, Varney KF, Khayam-Bashi H, Murphy EL. Are HTLV-II-seroposilive injection drug users at increased risk of bacterial pneumonia, abscess, and lymphadenopathy? J Acquir Immune Defic Svndr Hum Retrovirol 1997;16:169-75.
12. Welles SL, Tachibana N, Orav EJ, Okayama A, Ishizaki J, Mueller NE. Changes in hematologic parameters among Japanese HTLV-I carriers. J Acquir Immune Defic Syndr Hum Retrovirol 1994;7: 92-7.
13. Fletcher MA, Gjerset GF, Hassett J, et al. Lymphocyte immunophenotypes among anti-HTLV-I/II-positive blood donors and recipients. J Acquir Immune Defic Syndr Hum Retrovirol 1991;4: 628-32.
14. Rosenblatt JD, Plaeger-Marshall S, Giorgi JV, et al. A clinical, hematologic and immunologic analysis of 21 HTLV-II infected intravenous drug users. Blood 1990;76:409-17.
15. Prince HE. American blood donors seropositive for human T-lymphotropic virus types I/II exhibit normal lymphocyte subsets. Transfusion 1990;30:787-90.
16. Gibbs WN, Lofters WS, Campbell M, et al. Non-Hodgkin lymphoma in Jamaica and its relation to adult T-cell leukemialymphoma. Ann Intern Med 1987;106:361-8.
17. Fukumoto S, Matsumoto T, Watanabe T, Takahashi H, Miyoshi I, Ogata E. Secretion of parathyroid hormone-like activity from human T-cell lymphotropic virus type I-infected lymphocytes. Can-cer Res 1989;49:3849-52.
18. Murphy EL, Wilks RJ, Morgan OS, et al. Health effects of human T-lymphotropic virus type I (HTLV-I) in a Jamaican cohort. Int J Epidemiol 1996;25:1090-7.
19. Prin L, Leguern M, Ameisen JC, et al. HTLV-I and malignant hypereosinophilic syndrome. Lancet 1988;2:569-70.
20. Chavance M, Monplaisir N, Schaffar-Deshayes L, Valette I, Frery N. Eosinophil count in healthy HTLV-I carriers. Lancet 1988;2: 1309.
21. Murphy EL, Glynn SA, Fridey J, et al. Increased prevalence of infectious diseases and other adverse outcomes in HTLV infected blood donors. J Infect Dis 1997;176:1468-75.
22. Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams' hematology, 5th ed. New York: McGraw-Hill, 1995.
23. Breslow NE, Day NE. The analysis of case-control studies: statistical methods in cancer research, vol. 1, IARC Scientific Publication No. 32. Lyons, France: International Agency for Research on Cancer, 1980:136-46.
24. Sargent JD, Stukel TA, Dalton MA, Freeman JL, Brown MJ. Iron deficiency anemia in Massachusetts communities: socioeconomic and demographic risk factors among children. Am J Public Health 1996;86:544-50.
25. Nair MP, Schwartz SA, Polasani R, Hou J, Sweet A, Chadha KC. Immunoregulatory effects of morphine on human lymphocytes. Clin Diagn Lab Immunol 1997;4:127-32.
26. Draper N, Smith H. Applied regression analysis, 2nd ed. New York: John Wiley and Sons, 1981.
27. SAS Institute, Inc. SAS/STAT user's guide, vers. 6, vols. 1 and 2, 4th ed. Cary, NC: SAS Institute Inc., 1989.
28. Kramer A, Jacobson S, Reuben JF, et al. Spontaneous lymphocyte proliferation in symptom-free HTLV-I positive Jamaicans. Lancet 1989;2:923-4.
29. Prince H, Kleinman S, Doyle M, Lee H, Swanson P. Spontaneous lymphocyte proliferation in vitro characterizes both HTLV-I and HTLV-II infection. J Acquir Immune Defic Syndr Hum Retrovirol 1990;3:1199-1200.
30. Greene WC, Leonard WJ, Wano Y, et al. Trans-activator gene of HTLV-II induces IL-2 receptor and IL-2 cellular gene expression. Science 1986;232:877-80.
31. Lal RB, Hjelle B, Rudolph D. Spontaneous proliferation of HTLV-II-infected peripheral blood lymphocytes: HLA-DR-driven, IL-2-dependent response. Microbiol Immunol 1992;36:865-72.
32. Drexler HG, Quentmeier H. Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells. Leukemia 1996;10:1405-21.
33. Nimer SD, Gasson JC, Hu K, et al. Activation of the GM-CSF promoter by HTLV-I and -II tax proteins. Oncogene 1989;4:671-6.
34. Feuer G, Fraser JK, Zack JA, Lee F, Feuer R, Chen IS. Human T-cell leukemia virus infection of human hematopoietic progenitor cells: maintenance of virus infection during differentiation in vitro and in vivo. J Virol 1996;70:4038-44.
35. Nakada K, Kohakura M, Komoda H, Hinuma Y. High incidence of HTLV-I antibody in carriers of Strongyloides stercoralis. Lancet 1984;1:633.
36. Terry S, Blattner WA, Neva FA, et al. Coincidental HTLV-I infection influences outcome of treatment of strongyloidiasis. West Indian Med J 1989;38(Suppl):36.
37. Abu-Ghazaleh RI, Kita H, Gleich GJ. Eosinophil activation and function in health and disease. Immunol Ser 1992;57:137-67.